Imunon, Inc. IMNN
Nasdaq · XNAS · stock · Pharmaceutical Preparations
Chart by TradingView
3/9
Piotroski F — financial health
-115.11
Altman Z″ — distress risk · distress
—
Dividend payout · no dividend
Financials (annual, from 10-K)
| FY | Revenue | Net income | Gross profit | Free cash flow | Equity |
|---|---|---|---|---|---|
| 2025 | — | -$14.5M | — | -$14.2M | $7.1M |
| 2024 | — | -$18.6M | — | -$18.9M | $4.2M |
| 2023 | — | -$19.5M | — | -$19.5M | $13.4M |
| 2022 | $500,000 | -$35.9M | — | -$23.4M | $29.3M |
| 2021 | $500,000 | -$20.8M | — | -$16.5M | $55.8M |
| 2020 | $500,000 | -$21.5M | — | -$15.6M | $18.6M |
Why these scores methodology →
Piotroski F-score: 3/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: -115.11 (distress)
- Working capital / assets 0.496
- Retained earnings / assets -34.285
- EBIT / assets -1.192
- Equity / liabilities 1.351
Source: SEC EDGAR filings · CIK 0000749647 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.